Form 8-K IOVANCE BIOTHERAPEUTICS, For: Feb 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices drop about 3% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Iovance Biotherapeutics (IOVA) price targets raised following FDA accelerated approval
February 20, 2024 1:59 PM ESTShares of Iovance Biotherapeutics (NASDAQ: IOVA) surged more than 37% Tuesday after the company announced the FDA has granted accelerated approval to its T cell immunotherapy, Amtagvi (lifileucel) suspension, to treat advanced melanoma after anti-PD-1 and targeted therapy.
The announcement prompted several price target increases from Wall Street... More
